Policy ForumMedicine

Enhanced: The Need for a Global HIV Vaccine Enterprise

See allHide authors and affiliations

Science  27 Jun 2003:
Vol. 300, Issue 5628, pp. 2036-2039
DOI: 10.1126/science.1086916

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A new collaborative model of research is needed to increase resources, to prioritize the R&D agenda of the major public- and private-sector stakeholders, and ultimately to increase the probability and shorten the time to development of effective HIV vaccines for global use. The thrust of our proposal is (i) to increase the scale and organization for solving science problems and developing novel HIV vaccine approaches; (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.